SCHEDULE: Qiming Venture Partners Discloses 9.99% Stake in Vor Biopharma

Qiming Venture Partners entities have filed a Schedule 13G, reporting an aggregate beneficial ownership of 9.99% in Vor Biopharma Inc. common stock, including shares from pre-funded warrants.

Summary

• Qiming Venture Partners VIII Investments, LLC, Qiming Venture Partners VIII-HC, L.P., Qiming GP VIII, LLC, and Qiming GP VIII-HC, LLC (collectively, the "Reporting Persons") have filed a Schedule 13G regarding their beneficial ownership in Vor Biopharma Inc.
• The Reporting Persons collectively beneficially own 9.99% of Vor Biopharma Inc.'s common stock.
• This ownership includes 371,420 common shares and 43,067 shares from Pre-Funded Warrants held by Qiming Venture Partners VIII Investments, LLC, exercisable within 60 days of September 24, 2025.
• It also includes 444,708 common shares and 51,564 shares from Pre-Funded Warrants held by Qiming Venture Partners VIII-HC, L.P., exercisable within 60 days of September 24, 2025.
• The total common stock outstanding as of September 24, 2025, was 9,022,080 shares, with an additional 94,631 common shares issuable from Pre-Funded Warrants within 60 days of that date.
• A "Beneficial Ownership Blocker" in the Pre-Funded Warrants precludes the exercise of warrants to the extent that, following exercise, the Reporting Persons would own more than 9.99% of the outstanding shares of common stock.
• The securities were acquired for investment purposes and not with the purpose or effect of changing or influencing the control of Vor Biopharma Inc.

Sentiment

Score: 6

Explanation: The filing is a routine disclosure of beneficial ownership by a passive investor. It indicates continued institutional interest in Vor Biopharma Inc. but does not contain new operational or financial information that would significantly alter sentiment.

Positives

• A significant institutional investor maintains a substantial stake, potentially indicating confidence in the company's long-term prospects.
• The "Beneficial Ownership Blocker" limits the concentration of ownership, which can be seen as a governance positive by some stakeholders.

Risks

• The filing itself does not detail specific risks related to Vor Biopharma's operations or financial health, as it is a beneficial ownership report.
• The existence of Pre-Funded Warrants means potential future dilution if fully exercised, although the "Beneficial Ownership Blocker" limits the immediate dilutive impact from these specific warrants held by the Reporting Persons.

Future Outlook

NA

Industry Context

Schedule 13G filings are common in the biotech industry, where venture capital firms often take significant stakes in early-stage companies. Qiming Venture Partners' continued substantial ownership in Vor Biopharma, a clinical-stage cell and gene therapy company, signals ongoing institutional interest in the sector and potentially in Vor's specific therapeutic pipeline. The 9.99% cap is a common strategy to avoid triggering more stringent reporting requirements (like Schedule 13D) or certain regulatory thresholds.

Comparison to Industry Standards

• Qiming Venture Partners is a well-known venture capital firm with a focus on healthcare and technology. Their investment in Vor Biopharma aligns with typical venture capital strategies of taking significant, but often passive, stakes in promising biotech companies.
• The use of pre-funded warrants is a standard financing mechanism in the biotech industry, allowing companies to raise capital while managing the immediate dilutive impact and providing investors with flexibility.
• The 9.99% beneficial ownership blocker is a common practice among institutional investors to remain below the 10% threshold that triggers additional regulatory scrutiny and insider trading rules under Section 16 of the Exchange Act.

Corporate Governance

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional shareholder's stake, potentially offering a signal of confidence. The beneficial ownership blocker limits the immediate dilutive impact from the warrants held by these specific investors.
• Company Management: Awareness of a significant, passive institutional investor.
• Regulatory Authorities: Fulfills SEC disclosure requirements for beneficial ownership.

Next Steps

• The Reporting Persons will continue to monitor their investment in Vor Biopharma Inc.
• Future amendments to this Schedule 13G will be filed if there are material changes to their beneficial ownership.

Key Dates

Recommendation

This is a routine Schedule 13G filing reporting a passive beneficial ownership stake by Qiming Venture Partners in Vor Biopharma Inc. It does not contain new financial results, operational updates, or strategic shifts that would warrant a change in investment recommendation. The filing confirms an existing institutional investment, which is generally a neutral to slightly positive signal, but provides no basis for a "buy" or "sell" decision. Therefore, a "hold" recommendation is appropriate as the filing itself does not alter the fundamental investment thesis.

Keywords

Vor Biopharma, VOR, Qiming Venture Partners, Schedule 13G, beneficial ownership, common stock, pre-funded warrants, institutional investment, biotech, biopharma, SEC filing